Insights
Search Results
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
4.21.26
Wilson Sonsini Advises Novo Holdings, Norwest, and Platanus on Ray Therapeutics’ $125 Million Series B
On April 21, 2026, Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degenerations, announced the closing of an upsized and oversubscribed $125 million Series B financing. The round was led by Janus Henderson Investors, with participation from additional new investors Adage Capital Management, Franklin Templeton, Invus, and Marshall Wace. The financing includes strong follow-on support from existing investors 4BIO Capital, Deerfield Management, MRL Ventures Fund (the therapeutics-focused corporate venture arm of Merck & Co), Norwest, Novo Holdings A/S, and Platanus. Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S, Norwest, and Platanus on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.30.26
Wilson Sonsini Advises Octopus Energy on Majority Stake Acquisition of Uplight
On March 24, 2026, Octopus Energy Group, a global clean energy and technology business driving the affordable, green energy system of the future, will cement its expansion in the U.S. by acquiring a majority stake in Uplight, a leading provider of customer engagement and flexibility management solutions that rapidly transform customer participation into dependable grid capacity. The deal is made in partnership with Schneider Electric, a global energy technology leader trusted by utilities worldwide, which will remain as a significant minority partner. The transaction is subject to customary regulatory approvals and is expected to complete later this year. Wilson Sonsini Goodrich & Rosati advised Octopus Energy on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.12.26
Wilson Sonsini Advises Replit on $400 Million Series D
On March 11, 2026, Georgian, a growth-stage B2B investor, announced it has led a $400 million Series D investment in Replit, an AI-powered development platform, valuing the company at $9 billion. G Squared, Prysm Capital, Coatue, Andreessen Horowitz (a16z), Craft Ventures, Y Combinator, Accenture Ventures, Okta Ventures, and Databricks Ventures also participated in the round. Wilson Sonsini Goodrich & Rosati advised Replit on the transaction.
Client Highlights
2.25.26
Wilson Sonsini Advises SambaNova on $350 Million Series E Financing
On February 24, 2026, SambaNova, a leader in next‑generation AI infrastructure, announced that it has raised more than $350 million in investment from new and existing investors. The oversubscribed Series E round was led by Vista Equity Partners and Cambium Capital, with strong participation from Intel Capital. Wilson Sonsini Goodrich & Rosati advised SambaNova on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
1.13.26
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Client Highlights
12.19.25
Wilson Sonsini Advises Cursor on Acquisition of Graphite
On December 19, 2025, Cursor, the leading AI development platform, announced that it has signed a definitive agreement to acquire Graphite, a start-up that uses AI to review code. The financial terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati advised Cursor on the transaction.
The transaction brings together best-in-class tools for creating, reviewing, and merging code in the AI age. Graphite will continue to operate independently, with the same team and product. According to Cursor, in the coming months the two companies will explore connecting their products, for instance with tighter integrations between local development and pull requests and smarter code review that learns from both systems.
The Wilson Sonsini team that advised Cursor on the transaction included:
M&A
Rich Mullen
Ryan Cooper
Hallee Moore
Valerie Lopez
Drew Downing
The transaction brings together best-in-class tools for creating, reviewing, and merging code in the AI age. Graphite will continue to operate independently, with the same team and product. According to Cursor, in the coming months the two companies will explore connecting their products, for instance with tighter integrations between local development and pull requests and smarter code review that learns from both systems.
The Wilson Sonsini team that advised Cursor on the transaction included:
M&A
Rich Mullen
Ryan Cooper
Hallee Moore
Valerie Lopez
Drew Downing
Client Highlights
12.05.25
Wilson Sonsini Advises Chronosphere on $3.35 Billion Acquisition by Palo Alto Networks
On November 19, 2025, global cybersecurity leader Palo Alto Networks announced that it has entered into a definitive agreement to acquire Chronosphere, a next-generation observability platform built to scale for the AI era, for total consideration of $3.35 billion. Wilson Sonsini Goodrich & Rosati advised Chronosphere on the transaction.
The combination of Chronosphere and Palo Alto Networks’ AgentiX platform will deliver real-time, agentic remediation for the world’s leading AI-native companies and strengthen Palo Alto Networks' ability to help organizations navigate a world where modern applications and AI workloads demand a unified data and security foundation. The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to close in Palo Alto Networks’ second half of fiscal year 2026.
The Wilson Sonsini team that advised Chronosphere on the acquisition was led by Damien Weiss, Todd Cleary, Jack Hamilton, and Rob Broderick, and also included:
The combination of Chronosphere and Palo Alto Networks’ AgentiX platform will deliver real-time, agentic remediation for the world’s leading AI-native companies and strengthen Palo Alto Networks' ability to help organizations navigate a world where modern applications and AI workloads demand a unified data and security foundation. The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to close in Palo Alto Networks’ second half of fiscal year 2026.
The Wilson Sonsini team that advised Chronosphere on the acquisition was led by Damien Weiss, Todd Cleary, Jack Hamilton, and Rob Broderick, and also included:
Client Highlights
9.30.25
Firm Advises Novo Holdings and SR One on Crystalys Therapeutics’ $205 Million Series A
On September 30, 2025, Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company, announced its launch with a $205 million Series A financing to support its mission of addressing the significant unmet medical needs of people living with gout. The financing was co-led by Novo Holdings, SR One, and Catalys Pacific, with participation from a broad syndicate of investors, including Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund. Wilson Sonsini Goodrich & Rosati advised co-lead investors Novo Holdings and SR One on the transaction.